HelpAcademyLoginJoin us as a Member

Biohaven Ltd.

Sign in to save Biohaven Ltd. to a watchlist Sign in to set an alert for Biohaven Ltd.
Tickers
BHVN
Headquarters
Not recorded
SEC CIK
0001935979
Website
Not recorded

Closing prices

Latest close, 16.49

Closing prices for BHVN249 stored closes for BHVN from 3 Nov 2025 to 29 Oct 2026. Lowest 7.79 on 10 Nov 2025, highest 16.95 on 26 Aug 2026, latest 16.49 on 29 Oct 2026.Close7.5010.0012.5015.0017.503 Nov 20251 May 202629 Oct 2026
249 stored closes, oldest first. End of day, not intraday.

Source: Massive Closing prices as of End-of-day prices, not live

Massive Basic, non-business use; display licence needed before launch (D-1). Marketstack is kept as the backup source.

Not investment advice. End-of-day closing prices, not live quotes.

Drugs

Drugs from Biohaven Ltd.
DrugIndicationsPhaseNext catalystCT-VCATrials
BHV-1300Not yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yet Sign in to save BHV-1300 to a watchlist Graves DiseasePhase 3None scheduledNo published CT-VCA score1
BHV-7000Not yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yet Sign in to save BHV-7000 to a watchlist Focal Epilepsy; Bipolar DisorderPhase 2/3None scheduledNo published CT-VCA score3
BHV-8000Not yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yet Sign in to save BHV-8000 to a watchlist Parkinson DiseasePhase 2/3None scheduledNo published CT-VCA score1
Taldefgrobep alfaNot yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yet Sign in to save Taldefgrobep alfa to a watchlist Neuromuscular Diseases; SMA; Spinal Muscular AtrophyPhase 3None scheduledNo published CT-VCA score1
TroriluzoleNot yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yet Sign in to save Troriluzole to a watchlist Obsessive-Compulsive Disorder; Spinocerebellar Ataxias; Spinocerebellar Ataxia Genotype Type 1; Spinocerebellar Ataxia Genotype Type 10; Spinocerebellar Ataxia Genotype Type 2Phase 3None scheduledNo published CT-VCA score5

FDA-approved applications

No Drugs@FDA application has a sponsor name that matches this company.

Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.

Catalysts

No catalysts yet. Editors add each date together with its source.

Deals

No approved deals involve this company yet.

Reported fundamentals (SEC XBRL)

Latest value of each metric as reported to the SEC
MetricReported valuePeriodFiling
RevenueNot reported in XBRL filings since 2015
Net income (loss)−129,279,000 USD 1 Jul 2026 to 30 Sep 2026 FY2026 Q310-Q for Net income (loss) on sec.gov (opens in a new tab)Filed
Research and development expense101,850,000 USD 1 Jul 2026 to 30 Sep 2026 FY2026 Q310-Q for Research and development expense on sec.gov (opens in a new tab)Filed
Operating expenses126,420,000 USD 1 Jul 2026 to 30 Sep 2026 FY2026 Q310-Q for Operating expenses on sec.gov (opens in a new tab)Filed
Cash and cash equivalents95,754,000 USD At 30 Sep 2026 FY2026 Q310-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed
Short-term investments and marketable securities65,371,000 USD At 30 Sep 2026 FY2026 Q310-Q for Short-term investments and marketable securities on sec.gov (opens in a new tab)Filed
Total liabilities361,923,000 USD At 30 Sep 2026 FY2026 Q310-Q for Total liabilities on sec.gov (opens in a new tab)Filed
Stockholders' equity−98,247,000 USD At 30 Sep 2026 FY2026 Q310-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed
Common shares outstanding (cover page)151,058,781 shares At 26 Oct 2026 FY2026 Q310-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed

History

Net income (loss), newest period first
PeriodReported valueFiling
1 Jul 2026 to 30 Sep 2026 FY2026 Q3−129,279,000 USD10-Q filed 29 Oct 2026 on sec.gov (opens in a new tab)Filed
1 Apr 2026 to 30 Jun 2026 FY2026 Q2−137,311,000 USD10-Q filed 10 Aug 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2026 to 31 Mar 2026 FY2026 Q1−130,532,000 USD10-Q filed 4 May 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2025 to 31 Dec 2025 FY2025−738,822,000 USD10-K filed 2 Mar 2026 on sec.gov (opens in a new tab)Filed
1 Jul 2025 to 30 Sep 2025 FY2026 Q3−173,443,000 USD10-Q filed 29 Oct 2026 on sec.gov (opens in a new tab)Filed
1 Apr 2025 to 30 Jun 2025 FY2026 Q2−198,147,000 USD10-Q filed 10 Aug 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2025 to 31 Mar 2025 FY2026 Q1−221,677,000 USD10-Q filed 4 May 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2024 to 31 Dec 2024 FY2025−846,422,000 USD10-K filed 2 Mar 2026 on sec.gov (opens in a new tab)Filed

The newest 12 periods of each metric are listed; older ones are on sec.gov.

Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.

Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-30 · read

SEC filings

SEC filings from Biohaven Ltd., newest first
FormFiledWhat it coversDocument
8-K Current report (8-K) View Current report (8-K) filed 29 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001935979-26-000093 (opens in a new tab)
10-Q Quarterly report (10-Q) View Quarterly report (10-Q) filed 29 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001935979-26-000092 (opens in a new tab)
8-K Current report (8-K)
  • Regulation FD disclosure (Item 7.01)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 22 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001935979-26-000083 (opens in a new tab)
8-KEvent 8 Oct 2026 Current report (8-K)
  • Entry into a material definitive agreement (Item 1.01)
  • Regulation FD disclosure (Item 7.01)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 15 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001935979-26-000080 (opens in a new tab)
4Event 15 Sep 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 17 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001704186-26-000006 (opens in a new tab)
8-KEvent 4 Sep 2026 Current report (8-K)
  • Other events (Item 8.01)
View Current report (8-K) filed 10 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001935979-26-000077 (opens in a new tab)
8-K Current report (8-K)
  • Entry into a material definitive agreement (Item 1.01)
  • Regulation FD disclosure (Item 7.01)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 26 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001935979-26-000072 (opens in a new tab)
8-K Current report (8-K)
  • Results of operations and financial condition (Item 2.02)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 10 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001935979-26-000067 (opens in a new tab)
10-QEvent 30 Jun 2026 Quarterly report (10-Q) View Quarterly report (10-Q) filed 10 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001935979-26-000066 (opens in a new tab)
8-KEvent 3 Aug 2026 Current report (8-K)
  • Departure or appointment of directors or officers (Item 5.02)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 7 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001935979-26-000060 (opens in a new tab)

Source: SEC EDGAR. Each row links to the filing on sec.gov.

Related news

Insider transactions

All rows for Biohaven Ltd. on Insider Trades

Last 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).

Buys code P
None in this period
Sells code S
None in this period
Other all other codes
None in this period

Last transaction:

Insider filings are public records and are not a recommendation. Source: SEC EDGAR.

Sources

Nothing on this page is investment advice.